Bruno Paiva, PhD, from the University of Navarra, Pamplona, Spain discusses the current status of novel treatments in multiple myleoma (MM). According to Dr Paiva, the last three years have seen important advances for transplant eligible and ineligible MM patients. There are two questions that need to be addressed: how to combine the new agents with the current backbone therapy and how to combine the various individual novel drugs.
Recorded at the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.